Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics

Impact · against what's priced in

Evotec is shifting toward a capital-light, technology-licensing model for biologics manufacturing via the launch of J.TRAIN. This diversification into turnkey services and recurring licensing revenue, validated by a transaction with Sandoz, improves the company's scalability and reduces its reliance on heavy internal capex.

EVO+0.60

No priced-in read yet